GreenLight Biosciences- Warrants (30/09/2027) Long Term Debt

The latest long-term debt for GRNAW is $60M as of March 2023. That compares with $24M in the prior-year period — up 151.5% year over year. Investors often review this figure alongside GreenLight Biosciences- Warrants (30/09/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, GRNAW's long-term debt moved from $24M to $60M — a 151.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GreenLight Biosciences- Warrants (30/09/2027)'s operating scale or balance-sheet position.

A long-term debt figure of $60M for GRNAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GRNAW's long-term debt ($60M), review year-over-year change from $24M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.